BBIO BridgeBio Pharma, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Biopharmaceutical development and commercialization with focus on genetic diseases and novel therapies
• • New emphasis on commercialization with FDA approval and US launch of Attruby (net product revenue $362.4M in 2025)
• • Strategic shift: Exclusive EU license of acoramidis to Bayer and sale of royalty rights generating $300M upfront cash
• • Increased SG&A expenses by $242.3M in 2025 supporting commercial launch of Attruby; R&D expenses decreased $54.5M due to program reprioritization
• • Raised $619.3M net from 0.75% convertible notes due 2033 in 2026, used partly for common stock repurchase and refinancing debt

Risk Factors

• • Cybersecurity risk managed by multidisciplinary Incident Response Team led by Director of Security with 20 years IT experience
• • Audit Committee oversees enterprise risks, including privacy and cybersecurity, with bi-annual reviews involving legal and executive leadership
• • Board of Directors receives periodic updates on cybersecurity risks and risk management from executive leadership
• • Data Privacy and Security Committee meets quarterly to discuss cybersecurity risk management and reports to Audit Committee

Management Discussion & Analysis

• • No revenue figures or YoY changes disclosed in provided text
• • No profitability or margin percentages reported
• • No segment performance details included
• • No cash flow, buybacks, dividends, or capex figures stated
• • Forward-looking risks and uncertainties highlighted, no specific guidance or outlook provided

What are the latest BBIO SEC filings in 2026?

BridgeBio Pharma, Inc. (BBIO) has filed a 10-K annual report on February 24, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on July 22, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did BBIO file its most recent 10-K annual report?

BridgeBio Pharma, Inc. (BBIO) filed its most recent 10-K annual report on February 24, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view BBIO 10-Q quarterly reports?

BridgeBio Pharma, Inc. (BBIO)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every BBIO 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has BBIO filed recently?

BridgeBio Pharma, Inc. (BBIO)'s most recent 8-K was filed on July 22, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find BBIO insider trading activity (Form 4)?

SignalX aggregates every BBIO Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does BBIO file with the SEC?

BridgeBio Pharma, Inc. (BBIO) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new BBIO filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for BridgeBio Pharma, Inc. (BBIO).

What is BBIO's SEC CIK number?

BridgeBio Pharma, Inc. (BBIO)'s SEC CIK (Central Index Key) number is 1743881. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1743881 to look up all BBIO filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find BBIO return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from BridgeBio Pharma, Inc. (BBIO) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.